Optim.AI®, developed by KYAN Technologies, is a cutting-edge functional precision medicine platform designed to revolutionize cancer care by predicting the optimal treatment for individual patients. By combining small data AI with biological experiments, the platform tests a patient’s cancer cells against a range of drugs. It predicts and ranks all possible drug-drug interactions, providing clinicians with insights into the most effective treatment options for their patients.

Optim.AI® stems from collaborations with prestigious institutions like UCLA and the National University of Singapore. Clinical studies have consistently demonstrated its robustness and accuracy across various cancer types. KYAN’s clinical lab has been accredited by the Ministry of Health (MOH) in Singapore since May 2023.